UK Companies House feature
TEVA UK HOLDCO 3 LIMITED
Profile
- Company number
- 12211029
- Status
- Active
- Incorporation
- 2019-09-17
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Subsidiaries
- Orvet UK · 100% held · United Kingdom · Holding company
- Teva Holdco US, Inc. · 100% held · United States · Holding company
- Anda Holdco Corp. · 100% held · United States · Holding company
- Anda Marketing, Inc. · 100% held · United States · Dormant company
- Anda Pharmaceuticals, Inc. · 100% held · United States · Wholesale distribution
- Anda, Inc. · 100% held · United States · Wholesale distribution
- Anda Puerto Rico Inc. · 100% held · United States · Dormant company
- Teva API, Inc. · 100% held · United States · Manufacturer
- Teva Digital Health, Inc. · 100% held · United States · Development, Marketing
- Teva Pharmaceuticals USA, Inc. · 100% held · United States · Manufacturing, Distribution, Marketing
- Actavis Holdco US, Inc. · 100% held · United States · Holding company
- Actavis Laboratories UT, Inc. · 100% held · United States · Manufacturing
- Actavis Puerto Rico Holdings Inc. · 100% held · United States · Marketing, Holding company
- Coventry Acquisition, LLC · 100% held · United States · Holding company
- Actavis Pharma, Inc. · 100% held · United States · Holding company
- Actavis Pharmaceuticals NJ, Inc. · 100% held · United States · Manufacturing, R&D
- Watson Laboratories, Inc [Connecticut] · 100% held · United States · Manufacturing
- Watson Pharma Private Limited · 100% held · India · Development, Manufacturing, Commercial, Distribution
- Andrx LLC · 100% held · United States · Holding company
- Actavis Laboratories FL, Inc. · 100% held · United States · Manufacturing
- Watson Management Corporation · 100% held · United States · Marketing
- Watson Therapeutics, Inc. · 100% held · United States · Marketing
- Circa Pharmaceuticals West, Inc. · 100% held · United States · Dormant company
- Royce Research and Development Limited Partnership I · 100% held · United States · Dormant company
- Watson Laboratories, Inc. [Nevada] · 100% held · United States · Holding company, Marketing, Manufacturing
- Actavis US Holding LLC · 100% held · United States · Holding company
- Actavis LLC · 100% held · United States · Manufacturing, Holding company
- Actavis Elizabeth LLC · 100% held · United States · Manufacturing
- Actavis Kadian LLC · 100% held · United States · Holding company
- Actavis Mid Atlantic LLC · 100% held · United States · Marketing, Holding company
- Actavis South Atlantic LLC · 100% held · United States · Manufacturing, Marketing
- Actavis Totowa LLC · 100% held · United States · Marketing
- Cobalt Laboratories LLC · 100% held · United States · Holding company
- Watson Laboratories, LLC · 100% held · United States · Holding company
- Watson Manufacturing Services, Inc. · 100% held · United States · Marketing
- Watson Pharmaceuticals (Asia) Limited · 100% held · British Virgin Islands · Holding company
- Changzhou Siyao Pharmaceuticals Co., Ltd. · 25% held · China · Dormant company
- Watson Pharmaceuticals (China) Limited · 100% held · British Virgin Islands · Holding company
- Med All Enterprise Consulting (Shanghai) Co., Limited · 100% held · China · Investment
- WP Holdings, Ltd. · 100% held · British Virgin Islands · Holding company
- Watson Pharmaceuticals International, Limited · 100% held · British Virgin Islands · Holding company
- ANTARES PHARMA INC. · 1% held · United States · Strategic Investment
- Auspex Pharmaceuticals LLC · 100% held · United States · Marketing, Manufacturing, API
- Barr Pharmaceuticals, LLC · 100% held · United States · Holding company
- Barr Laboratories LLC · 100% held · United States · Manufacturing
- Barr International Services, Inc. · 100% held · United States · Holding company
- PLIVA, Inc. · 100% held · United States · Holding company
- Odyssey Pharmaceuticals, Inc. · 100% held · United States · Shelf finance company
- Teva Women's Health, LLC · 100% held · United States · Manufacturing, Marketing
- Teva Sales and Marketing, Inc. · 100% held · United States · Holding company, Marketing
- Cupric Holding Co. LLC · 100% held · United States · Holding company
- Cephalon, LLC · 100% held · United States · Holding company, Marketing
- Anesta LLC · 100% held · United States · Manufacturing
- Cephalon Development Corporation · 100% held · United States · Holding company
- Cephalon Clinical Partners, LP · 100% held · United States · Dormant company
- CIMA Labs, Inc. · 100% held · United States · Manufacturing
- East End Insurance, Ltd. · 100% held · Bermuda · Insurance
- Gecko Health Innovations, Inc. · 100% held · United States · Commercial, Investment, Manufacturing
- IVAX LLC · 100% held · United States · Holding company
- IVAX Pharmaceuticals Mexico, S.A. de C.V. · 100% held · Mexico · Distribution, Manufacturing, Marketing
- IVAX (Bermuda) Ltd. · 100% held · Bermuda · Holding company
- IVAX Argentina S.A. · 100% held · Argentina · Manufacturing, Marketing
- IVAX Far East, Inc. · 100% held · United States · Dormant company
- China National Pharmaceutical Logistics Corp. LTD · 10% held · China · Strategic Investment
- IVAX Holdings C.I. · 100% held · Cayman Islands · Holding company
- Laboratorio Chile, S.A. · 100% held · Chile · Manufactures, sells, markets and distributes medicines
- LBC International Corp. · 100% held · Cayman Islands · Dormant company
- Pharmatrade S.A. · 100% held · Chile · Commercial, Manufacturing
- Teva Pharmaceuticals Colombia S A S · 100% held · Colombia · Distribution, Manufacturing
- TEVA INVERSIONES Y EXPORTACIONES SpA · 100% held · Chile · Commercial, Marketing, Distribution
- IVAX Pharmaceuticals, LLC · 100% held · United States · Holding company, Marketing
- Doral Manufacturing, Inc. · 100% held · United States · Manufacturing
- Goldline Laboratories, Inc. · 100% held · United States · Marketing
- IVAX Pharmaceuticals NV, LLC · 100% held · United States · Holding company
- IVAX Pharmaceuticals Caribe, Inc. · 100% held · United States · Manufacturing
- IVAX Specialty Chemicals Sub, LLC · 100% held · United States · Holding company
- Maancirkel Holding B.V. · 100% held · Netherlands · Holding company
- Inmobiliaria Lemery, S.A. de C.V. · 100% held · Mexico · Commercial
- Patient Services and Solutions, Inc. · 100% held · United States · Holding company
- TAPI Puerto Rico, Inc. · 100% held · Puerto Rico · API, Manufacturing
- Teva Branded Pharmaceutical Products R&D LLC · 100% held · United States · Holding company
- Teva Neuroscience, Inc. · 100% held · United States · Marketing
- Teva Pharmaceuticals Panama, S.A. · 100% held · Panama · Commercial, Marketing
- Teva Respiratory, LLC · 100% held · United States · Manufacturing, Marketing
- IVAX Laboratories Puerto Rico, Inc. · 100% held · United States · Dormant company
- TEVA Uruguay S.A. · 100% held · Uruguay · Commercial, Distribution, Manufacturing
- Labrys Biologics, Inc. · 100% held · United States · R&D
- MicroDose Therapeutx, Inc. · 100% held · United States · Commercial, Investment, Manufacturing
- Sicor Inc. · 100% held · United States · Commercial, Manufacturing, Marketing
- Rakepoll Holding B.V. · 100% held · Netherlands · Holding company
- Lemery S.A. de C.V. · 100% held · Mexico · Manufacturing
- Sicor de México S.A. de C.V. · 100% held · Mexico · API, Manufacturing
- TEVA Pharmaceuticals Mexico S.A. de C.V. · 100% held · Mexico · Commercial
- UAB Teva Baltics · 100% held · Lithuania · Commercial, Manufacturing
- Teva Parenteral Medicines, Inc. · 100% held · United States · Manufacturing
- Teva Biopharmaceuticals USA, Inc. · 100% held · United States · R&D
- Teva Pharmaceutical Finance Company, LLC · 100% held · United States · Finance company
- Teva Pharmaceutical Finance IV, LLC · 100% held · United States · Finance company
- Teva Pharmaceutical Finance Netherlands III B.V. · 100% held · Netherlands · Finance company
- Teva Pharmaceutical Finance V, LLC · 100% held · United States · Dormant company
- Teva Pharmaceutical Finance VI, LLC · 100% held · United States · Dormant company
- Teton Pharmaceuticals, LLC · 100% held · United States · Licence holder
- GeminX Pharmaceuticals Canada, Inc. · 100% held · Canada · Dormant company
- Corporacion Medco CA · 100% held · Ecuador · Pharmaceutical Sales
- Schein Pharmaceuticals Bermuda Limited · 100% held · Bermuda · Pharmaceutical Sales
- Representaciones E Investigaciones Medicas SA · Mexico · Manufacturing
- Immobiliaria Leyfe, SA de C.V. · Mexico · Equipment Rental
- Inter Lab Pharmaceutica, SA de C.V. · Mexico · Manufacturing
- Watson Laboratories S. de R.L. de C.V. · 50% held · Mexico · Pharmaceutical Sales
- New Caribe CFC · 100% held · United States · Dormant company
- Teva API Services Mexico S de RL de C.V. · 50% held · Mexico · Outsourcing Services
Significant events
- “During March 2024, a loan receivable from a fellow group company of USD 900,000,000 with a maturity date of 24 March 2024 was extended to 24 March 2034, and loan payables to fellow group companies of USD 900,000,000 with a maturity date of 24 March 2024 were also extended to 24 March 2034.”
- “In June 2024, a series of cash transactions were undertaken to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 3 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva UK Holdco 2 Limited, 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 1,101,893,094.26.”
- “In August 2024, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 3 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva UK Holdco 2 Limited, 457,273,600 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 457,273,600.”
- “In December 2024 the company entered into a share exchange agreement with its ultimate parent company, Teva Pharmaceutical Industries Ltd and this had the effect on Teva UK Holdco 3 Limited as described below: Under the share exchange agreement, the company allotted one ordinary share of USD 1.00 credited as fully paid to Teva Pharmaceutical Industries Ltd, in exchange for a USD 1.00 on-demand interest-free receivable and one ordinary share of USD 1.00 in the capital of the company's direct subsidiary, Orvet UK.”
- “At the balance sheet date, the directors undertook an exercise to estimate the recoverable value of the company's fixed asset investments, which resulted in a reversal of impairment of USD 4,048,486,000 during the year (2023: impairment of USD 2,000,244,000).”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| COOPER, Dean Michael | Director | 2019-09-17 | Sep 1972 | British |
| KATZ, Yaron Aizik, Mr | Director | 2022-05-07 | Dec 1968 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HERMAN, Doron | Director | 2019-09-17 | 2022-05-07 |
| INNES, Kim | Director | 2019-09-17 | 2020-04-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Uk Holdco 1 Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-05-06 | Active |
| Teva Uk Holdco 2 Limited | Corporate entity | Shares 50–75%, Voting 50–75% | 2019-10-07 | Active |
| Orvet Uk | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-17 | Ceased 2019-10-07 |
Filing timeline
Last 20 of 39 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-01-20 | RP01SH01 | miscellaneous | legacy |
| 2025-10-06 | AA | accounts | accounts with accounts type full |
| 2025-09-29 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-08-14 | SH01 | capital | capital allotment shares |
| 2025-02-17 | SH01 | capital | capital allotment shares |
| 2025-01-30 | SH01 | capital | capital allotment shares |
| 2024-12-12 | RP04CS01 | confirmation-statement | second filing of confirmation statement with made up date |
| 2024-12-10 | SH01 | capital | capital allotment shares |
| 2024-10-21 | CS01 | confirmation-statement | confirmation statement |
| 2024-10-09 | AA | accounts | accounts with accounts type full |
| 2024-06-25 | SH01 | capital | capital allotment shares |
| 2023-12-14 | SH01 | capital | capital allotment shares |
| 2023-10-03 | CS01 | confirmation-statement | confirmation statement with updates |
| 2023-08-15 | AA | accounts | accounts with accounts type full |
| 2023-01-03 | AA | accounts | accounts with accounts type full |
| 2022-09-23 | CS01 | confirmation-statement | confirmation statement with updates |
| 2022-06-22 | SH01 | capital | capital allotment shares |
| 2022-05-11 | TM01 | officers | termination director company with name termination date |
| 2022-05-09 | AP01 | officers | appoint person director company with name date |
| 2021-11-12 | SH01 | capital | capital allotment shares |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Composite activity score · components 0–100 · reference 2026-05-10
48.3
COOL
/ 100
- Filings velocity 33
- Capital events 100
- Officer churn 0
- Headcount trajectory 50
- Accounts trajectory 50
- 4 filing(s) in last 12 months
- 5 capital event(s) in last 24 months